Inflammatory Breast Neoplasms

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Also Known As:
Inflammatory Breast Cancer (IBC); Inflammatory Breast Carcinoma; Breast Cancer, Inflammatory; Breast Cancers, Inflammatory; Breast Carcinoma, Inflammatory; Breast Carcinomas, Inflammatory; Breast Neoplasm, Inflammatory; Breast Neoplasms, Inflammatory; Cancer, Inflammatory Breast; Cancers, Inflammatory Breast; Carcinoma, Inflammatory Breast; Carcinomas, Inflammatory Breast; Inflammatory Breast Cancers; Inflammatory Breast Carcinomas; Inflammatory Breast Neoplasm; Neoplasm, Inflammatory Breast; Neoplasms, Inflammatory Breast; Inflammatory Breast Cancer
Networked: 457 relevant articles (32 outcomes, 73 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Breast Neoplasms (Breast Cancer)
2. Neoplasms (Cancer)
3. Neoplasm Metastasis (Metastasis)
4. Noninfiltrating Intraductal Carcinoma (DCIS)
5. Carcinoma (Carcinomatosis)


1. Cristofanilli, Massimo: 24 articles (11/2015 - 02/2004)
2. Ueno, Naoto T: 16 articles (06/2015 - 02/2008)
3. Woodward, Wendy A: 13 articles (12/2015 - 07/2007)
4. Merajver, Sofia D: 11 articles (06/2010 - 01/2002)
5. Vermeulen, Peter B: 10 articles (06/2015 - 09/2003)
6. Hortobagyi, Gabriel N: 10 articles (01/2014 - 02/2004)
7. van Golen, Kenneth L: 9 articles (06/2015 - 01/2002)
8. Barsky, Sanford H: 9 articles (01/2013 - 05/2002)
9. Dirix, Luc Y: 9 articles (10/2012 - 09/2003)
10. Bertucci, François: 8 articles (06/2015 - 12/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Inflammatory Breast Neoplasms:
1. lapatinib (GW572016)FDA Link
2. Paclitaxel (Taxol)FDA LinkGeneric
3. Epirubicin (Ellence)FDA LinkGeneric
4. trastuzumab (Herceptin)FDA Link
5. Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
07/01/2000 - "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. "
11/01/1999 - "The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. "
01/01/1993 - "The Dana-Farber Cancer Institute/Beth Israel Hospitals have developed the high-dose intensification regimen of cyclophosphamide, thiotepa, and carboplatin (CTCb) for use in women with metastatic and high-risk stage IIIB/inflammatory breast cancer. "
01/01/1994 - "Women were treated on one of six protocols: four sequential phase II protocols for metastatic breast cancer involving cyclophosphamide at a dose of 6000 mg/m2, thiotepa at 500 mg/m2, and carboplatin at 800 mg/m2 (CTCb) chemotherapy; one phase II study of CTCb chemotherapy for stage III or inflammatory breast cancer; and a Cancer and Leukemia Group B phase III study of cyclophosphamide, carmustine, and cisplatin for women with more than 10 involved lymph nodes after primary therapy. "
01/01/1986 - "In the present study 145 patients, including 67 with inflammatory breast cancer (IBC), were treated with 4-6 weeks of Velbe, thiotepa, methotrexate, fluorouracil and prednisone, with Adriblastin added for patients with IBC, T greater than 7 cm, or N2, N3. "
6. Cisplatin (Platino)FDA LinkGeneric
7. bevacizumabFDA Link
8. Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/01/2000 - "This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial (PEGASE 02), a French pilot multicenter trial of the treatment of inflammatory breast cancer (IBC) aimed at evaluating (1) toxicity and feasibility of sequential high-dose chemotherapy (HDC) with recombinant human granulocyte colony-stimulating factor (filgrastim) and stem-cell support and (2) response to HDC in terms of pathologic response and survival. "
04/01/2001 - "A total of 47 G-CSF mobilized stem cell grafts from patients with nodal-positive (n = 30), chemosensitive metastatic (n = 11), and 5 women with inflammatory breast cancer were evaluated for cancer cells by immunocytochemistry. "
03/10/2011 - "Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm). "
07/01/1995 - "To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral nonmetastatic inflammatory breast cancer treated with fluorouracil, epirubicin, and cyclophosphamide high-dose (FEC-HD) neoadjuvant chemotherapy. "
01/01/1999 - "The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinical and pathological remission rates and changes of immunohistochemical characteristics (ER, PR, c-erbB2, p53) during chemotherapy of inoperable patients (pt) with poor prognosis (locally advanced (LABC, 9 pt), inflammatory breast cancer (IBC, 12 pt) and M0. "
9. Filgrastim (Neupogen)FDA Link
10. Melphalan (Alkeran)FDA LinkGeneric
07/01/2000 - "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease > or =10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. "
08/01/2012 - "In this study, patients initiated high-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V. Eighty-six patients were diagnosed with locally advanced/inflammatory (17 inflammatory) breast cancer, and 12 were diagnosed with oligometastatic breast cancer. "
09/01/1990 - "Pulmonary function tests (standard vital capacity, SVC; total lung capacity, TLC; forced expiratory volume in 1 second-forced vital capacity ratio, FEV1/FVC; carbon monoxide transfer factor, DLCO) were prospectively evaluated in patients (median age 25 years, 13-52 years; median follow-up 20 months, 6-51 months) with Hodgkin's disease (15 patients), non-Hodgkin's lymphoma (9 patients), and inflammatory breast cancer (3 patients) treated with sequential high-dose therapy comprising the following phases over approximately 2 months: a) cyclophosphamide (7 g/m2); b) vincristine (1.4 mg/m2), methotrexate (8 g/m2), and cisplatinum (120 mg/m2) or etoposide (2 g/m2); c) total body irradiation (TBI; 12.5 gy, 5 fractions over 48 hours), intravenous melphalan (120-180 mg/m2), and transplantation of autologous peripheral blood and/or bone marrow hematopoietic stem cells. "

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Radiotherapy
3. Mastectomy (Mammectomy)
4. Segmental Mastectomy (Lumpectomy)
5. Neoadjuvant Therapy